Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too ...

Eli Lilly & Co. closed $63.38 below its 52-week high ($972.53), which the company reached on August 22nd.

Eli Lilly sued three medical spas and online vendors for selling products that claim to contain the ingredient in its ...

Spirit Airlines (SAVE) extends its debt refinancing deadline with the US Bank National Association, sending the stock soaring ...

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) is having a terrific 2024. Shares have gained 58% so far this year, handily ...

Eli Lilly sues vendors for selling unauthorized tirzepatide amid resolved shortages. Lawsuits target vendors offering ...

Led by Sen. Dick Durbin of Illinois, senators question if direct-to-consumer website telehealth deals are a new way around ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

As an investor in Eli Lilly stock, I'm encouraged by the company's forward thinking. Not only is management making moves to ...

MangoRx was responding to Eli Lily after the drugmaker sued it and two other medical spas and online vendors earlier this ...

Mangoceuticals (MGRX) learned earlier this morning that Eli Lilly (LLY) has made certain public claims alleging, and has stated that it ...